Ibrance (palbociclib) — United Healthcare
Well-Differentiated/Dedifferentiated Liposarcoma (WD-DDLS)
Initial criteria
- Diagnosis of unresectable retroperitoneal WD-DDLS
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Ibrance therapy
Approval duration
12 months